{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:31:28Z","timestamp":1787391088091,"version":"build-2736575974"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,8]]},"DOI":"10.7759\/cureus.110454","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:19:15Z","timestamp":1780928355000},"source":"Crossref","is-referenced-by-count":1,"title":["Severe Inflammatory Cystitis and Ureteritis Following Neoadjuvant TCHP (Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab) Therapy in HER2-Positive Breast Cancer: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Navin","family":"Mathiyalagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rahul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Adeel","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiman Abdelmoneim","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/0970-1591.65380","article-title":"Hemorrhagic cystitis: a challenge to the urologist","volume":"26","author":"Manikandan R","year":"2010","unstructured":"Manikandan R, Kumar S, Dorairajan LN. Hemorrhagic cystitis: a challenge to the urologist. Indian J Urol. 2010, 26:159-66. 10.4103\/0970-1591.65380","journal-title":"Indian J Urol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10565-006-0078-0","article-title":"Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation","volume":"23","author":"Korkmaz A","year":"2007","unstructured":"Korkmaz A, Topal T, Oter S. Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol. 2007, 23:303-12. 10.1007\/s10565-006-0078-0","journal-title":"Cell Biol Toxicol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S40601","article-title":"Presentation and management of docetaxel-related adverse effects in patients with breast cancer","volume":"6","author":"Ho MY","year":"2014","unstructured":"Ho MY, Mackey JR. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res. 2014, 6:253-9. 10.2147\/CMAR.S40601","journal-title":"Cancer Manag Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss A","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, et al.. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013, 24:2278-84. 10.1093\/annonc\/mdt182","journal-title":"Ann Oncol"},{"key":"ref5","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 2.2026. (2026). Accessed: May 9, 2026: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000041906","article-title":"Unraveling the Crimson puzzle: two case reports\/case series of hemorrhagic cystitis after combination chemotherapy with docetaxel, carboplatin, trastuzumab and pertuzumab in breast cancer","volume":"104","author":"Ramirez JC","year":"2025","unstructured":"Ramirez JC, Lacey ME, Gowda MS, Wang G, Chamorro Y, Sandoval-Leon AC. Unraveling the Crimson puzzle: two case reports\/case series of hemorrhagic cystitis after combination chemotherapy with docetaxel, carboplatin, trastuzumab and pertuzumab in breast cancer. Medicine (Baltimore). 2025, 104:e41906. 10.1097\/MD.0000000000041906","journal-title":"Medicine (Baltimore)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-245407","article-title":"Gross hematuria secondary to use of carboplatin in neoadjuvant treatment of breast cancer with HER2 overexpression","volume":"15","author":"Pastorello J","year":"2022","unstructured":"Pastorello J, da Silva NA, Schuch NB, Lando E. Gross hematuria secondary to use of carboplatin in neoadjuvant treatment of breast cancer with HER2 overexpression. BMJ Case Rep. 2022, 15:10.1136\/bcr-2021-245407","journal-title":"BMJ Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3181dcf744","article-title":"Carboplatin-induced hematuria in a patient of breast carcinoma. A case report","volume":"18","author":"Taj A","year":"2011","unstructured":"Taj A, Vijendra D, Shafiq Q, Mohamed I. Carboplatin-induced hematuria in a patient of breast carcinoma. A case report. Am J Ther. 2011, 18:e269-70. 10.1097\/MJT.0b013e3181dcf744","journal-title":"Am J Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1258474","article-title":"Case report: Urothelial injury in a female with breast cancer: a rare adverse event after the combination of paclitaxel and trastuzumab","volume":"13","author":"Cao T","year":"2023","unstructured":"Cao T, Duan Z, Zhu J, et al.. Case report: Urothelial injury in a female with breast cancer: a rare adverse event after the combination of paclitaxel and trastuzumab. Front Oncol. 2023, 13:1258474. 10.3389\/fonc.2023.1258474","journal-title":"Front Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/499033-severe-inflammatory-cystitis-and-ureteritis-following-neoadjuvant-tchp-docetaxel-carboplatin-trastuzumab-and-pertuzumab-therapy-in-her2-positive-breast-cancer-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:19:19Z","timestamp":1780928359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/499033-severe-inflammatory-cystitis-and-ureteritis-following-neoadjuvant-tchp-docetaxel-carboplatin-trastuzumab-and-pertuzumab-therapy-in-her2-positive-breast-cancer-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.110454","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,8]]}}}